Ok_老虎社区_美港股上老虎

huathuatking
2021-12-08

Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote>

Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on

Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":602309167,"tweetId":"602309167","gmtCreate":1638966639962,"gmtModify":1638966640136,"author":{"id":3572923710314905,"idStr":"3572923710314905","authorId":3572923710314905,"authorIdStr":"3572923710314905","name":"huathuatking","avatar":"https://static.tigerbbs.com/2f213995240eaab2cd1ce03e0a2cde28","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Ok</body></html>","htmlText":"<html><head></head><body>Ok</body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/602309167","repostId":1177589023,"repostType":4,"repost":{"id":"1177589023","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohu8.com/m/news/1177589023?lang=zh_CN&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.<blockquote>辉瑞和biontech股票在提供奥密克戎变种的最新信息后，在盘前交易中收窄了跌幅。</blockquote> <img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> <ul> <li>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</li> <li>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</li> <li>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</li> <li>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</li> </ul> Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;laboratory&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.<blockquote><ul><li>初步实验室研究表明，三剂辉瑞-BioNTech新冠肺炎疫苗中和了奥密克戎变异体（B.1.1.529谱系），而两剂显示中和滴度显著降低</li><li>数据表明，与针对奥密克戎变体的两个剂量相比，第三个剂量的BNT162b2使中和抗体滴度增加了25倍；加强剂量后的滴度与针对野生型病毒的两次剂量后观察到的滴度相当，其与高水平的保护相关</li><li>由于CD8+T细胞识别的刺突蛋白中80%的表位不受奥密克戎变异体突变的影响，两次剂量仍可能诱导对严重疾病的保护</li><li>两家公司继续推进针对奥密克戎病毒的变异特异性疫苗的开发，预计如果需要进行调整以进一步提高保护水平和持续时间，将在3月份之前上市-预计两家公司的疫苗不会发生变化2022年40亿剂产能</li></ul>辉瑞公司和BioNTech SE今天公布了初步结果实验室研究表明，辉瑞-BioNTech新冠肺炎疫苗（BNT162b2）诱导的血清抗体在三剂后中和新型冠状病毒奥密克戎变异体。在接受加强疫苗接种（第三剂BNT162b2疫苗）后一个月从接种者获得的血清中和了奥密克戎变异体，其水平与两剂后观察到的野生型新型冠状病毒刺突蛋白相当。</blockquote> Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.<blockquote>与野生型相比，接受两剂当前新冠肺炎疫苗的个体的血清对奥密克戎变异体的中和滴度平均降低了25倍以上，这表明两剂BNT162b2可能不足以预防奥密克戎变异体的感染。然而，由于疫苗诱导的T细胞靶向的绝大多数表位不受奥密克戎病突变的影响，两家公司认为，接种疫苗的个体可能仍然可以预防严重形式的疾病，并正在密切监测全球范围内针对奥密克戎的真实有效性。</blockquote> A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.<blockquote>第三剂可以实现更强大的保护，因为两家公司的其他研究数据表明，辉瑞和BioNTech的当前新冠肺炎疫苗的加强剂可以将抗体滴度提高25倍。根据两家公司的初步数据，第三剂疫苗提供的奥密克戎中和抗体水平与针对野生型和奥密克戎之前出现的其他变种的两剂疫苗后观察到的相似。这些抗体水平与针对野生型病毒和这些变体两者的高功效相关。第三剂量还强烈增加针对多个刺突蛋白表位的CD8+T细胞水平，所述多个刺突蛋白表位被认为与针对严重疾病的保护相关。与野生型病毒相比，这些表位中的绝大多数在奥密克戎刺突变体中保持不变。</blockquote> “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”<blockquote>“虽然两剂疫苗可能仍然可以预防由奥密克戎毒株引起的严重疾病，但从这些初步数据可以清楚地看出，第三剂我们的疫苗可以提高保护作用，”他说。Albert Bourla，辉瑞公司董事长兼首席执行官.“确保尽可能多的人完全接种前两剂系列疫苗和加强剂仍然是防止COVID-19传播的最佳行动方案。”</blockquote> “Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”<blockquote>“我们的初步、第一个数据集表明，第三剂疫苗仍然可以提供足够的保护，预防由奥密克戎变种引起的任何严重程度的疾病，”他说。Ugur Sahin，医学博士，BioNTech首席执行官兼联合创始人“世界各地广泛的疫苗接种和加强疫苗接种活动可以帮助我们更好地保护世界各地的人们并度过冬季。我们继续研究一种适应性疫苗，我们相信这将有助于诱导针对奥密克戎引起的COVID-19疾病的高水平保护，与目前的疫苗相比，保护时间更长。”</blockquote> While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.<blockquote>虽然这些结果是初步的，但两家公司将继续收集更多的实验室数据并评估现实世界的有效性，以评估和确认对奥密克戎的保护，并为最有效的前进道路提供信息。11月25日，两家公司开始开发一种针对奥密克戎的COVID-19疫苗。如果需要调整疫苗以提高对奥密克戎的保护水平和持续时间，开发将按计划继续进行。第一批基于奥密克戎的疫苗可以生产，并计划在100天内准备好交付，等待监管部门的批准。辉瑞和BioNTech也测试了其他变异特异性疫苗，这些疫苗产生了非常强的中和滴度和可耐受的安全性。基于这一经验，这些公司非常有信心，如果需要，他们可以在2022年3月交付基于奥密克戎的疫苗。这些公司此前还启动了变异特异性疫苗（Alpha、Beta、Delta和Alpha/Delta Mix）的临床试验，这些研究的数据将提交给世界各地的监管机构，以帮助加快适应疫苗的过程，并在需要时获得奥密克戎特异性疫苗的监管授权或批准。两家公司此前曾宣布，他们预计在2022年生产40亿剂BNT162b2，如果需要适应的疫苗，预计这一产能不会改变。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-12-08 20:00\n</div>\n</a>\n</h4>\n</header>\n<article>\nPfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.<blockquote>辉瑞和biontech股票在提供奥密克戎变种的最新信息后，在盘前交易中收窄了跌幅。</blockquote> <img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> <ul> <li>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</li> <li>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</li> <li>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</li> <li>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</li> </ul> Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;laboratory&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.<blockquote><ul><li>初步实验室研究表明，三剂辉瑞-BioNTech新冠肺炎疫苗中和了奥密克戎变异体（B.1.1.529谱系），而两剂显示中和滴度显著降低</li><li>数据表明，与针对奥密克戎变体的两个剂量相比，第三个剂量的BNT162b2使中和抗体滴度增加了25倍；加强剂量后的滴度与针对野生型病毒的两次剂量后观察到的滴度相当，其与高水平的保护相关</li><li>由于CD8+T细胞识别的刺突蛋白中80%的表位不受奥密克戎变异体突变的影响，两次剂量仍可能诱导对严重疾病的保护</li><li>两家公司继续推进针对奥密克戎病毒的变异特异性疫苗的开发，预计如果需要进行调整以进一步提高保护水平和持续时间，将在3月份之前上市-预计两家公司的疫苗不会发生变化2022年40亿剂产能</li></ul>辉瑞公司和BioNTech SE今天公布了初步结果实验室研究表明，辉瑞-BioNTech新冠肺炎疫苗（BNT162b2）诱导的血清抗体在三剂后中和新型冠状病毒奥密克戎变异体。在接受加强疫苗接种（第三剂BNT162b2疫苗）后一个月从接种者获得的血清中和了奥密克戎变异体，其水平与两剂后观察到的野生型新型冠状病毒刺突蛋白相当。</blockquote> Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.<blockquote>与野生型相比，接受两剂当前新冠肺炎疫苗的个体的血清对奥密克戎变异体的中和滴度平均降低了25倍以上，这表明两剂BNT162b2可能不足以预防奥密克戎变异体的感染。然而，由于疫苗诱导的T细胞靶向的绝大多数表位不受奥密克戎病突变的影响，两家公司认为，接种疫苗的个体可能仍然可以预防严重形式的疾病，并正在密切监测全球范围内针对奥密克戎的真实有效性。</blockquote> A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.<blockquote>第三剂可以实现更强大的保护，因为两家公司的其他研究数据表明，辉瑞和BioNTech的当前新冠肺炎疫苗的加强剂可以将抗体滴度提高25倍。根据两家公司的初步数据，第三剂疫苗提供的奥密克戎中和抗体水平与针对野生型和奥密克戎之前出现的其他变种的两剂疫苗后观察到的相似。这些抗体水平与针对野生型病毒和这些变体两者的高功效相关。第三剂量还强烈增加针对多个刺突蛋白表位的CD8+T细胞水平，所述多个刺突蛋白表位被认为与针对严重疾病的保护相关。与野生型病毒相比，这些表位中的绝大多数在奥密克戎刺突变体中保持不变。</blockquote> “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”<blockquote>“虽然两剂疫苗可能仍然可以预防由奥密克戎毒株引起的严重疾病，但从这些初步数据可以清楚地看出，第三剂我们的疫苗可以提高保护作用，”他说。Albert Bourla，辉瑞公司董事长兼首席执行官.“确保尽可能多的人完全接种前两剂系列疫苗和加强剂仍然是防止COVID-19传播的最佳行动方案。”</blockquote> “Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”<blockquote>“我们的初步、第一个数据集表明，第三剂疫苗仍然可以提供足够的保护，预防由奥密克戎变种引起的任何严重程度的疾病，”他说。Ugur Sahin，医学博士，BioNTech首席执行官兼联合创始人“世界各地广泛的疫苗接种和加强疫苗接种活动可以帮助我们更好地保护世界各地的人们并度过冬季。我们继续研究一种适应性疫苗，我们相信这将有助于诱导针对奥密克戎引起的COVID-19疾病的高水平保护，与目前的疫苗相比，保护时间更长。”</blockquote> While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.<blockquote>虽然这些结果是初步的，但两家公司将继续收集更多的实验室数据并评估现实世界的有效性，以评估和确认对奥密克戎的保护，并为最有效的前进道路提供信息。11月25日，两家公司开始开发一种针对奥密克戎的COVID-19疫苗。如果需要调整疫苗以提高对奥密克戎的保护水平和持续时间，开发将按计划继续进行。第一批基于奥密克戎的疫苗可以生产，并计划在100天内准备好交付，等待监管部门的批准。辉瑞和BioNTech也测试了其他变异特异性疫苗，这些疫苗产生了非常强的中和滴度和可耐受的安全性。基于这一经验，这些公司非常有信心，如果需要，他们可以在2022年3月交付基于奥密克戎的疫苗。这些公司此前还启动了变异特异性疫苗（Alpha、Beta、Delta和Alpha/Delta Mix）的临床试验，这些研究的数据将提交给世界各地的监管机构，以帮助加快适应疫苗的过程，并在需要时获得奥密克戎特异性疫苗的监管授权或批准。两家公司此前曾宣布，他们预计在2022年生产40亿剂BNT162b2，如果需要适应的疫苗，预计这一产能不会改变。</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2652,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote>

评论（1）

热议股票